Assay.Works GmbH (Gesellschaft mit beschränkter Haftung)
Am BioPark 11
93053 Regensburg, Germany
Dr. Ralf Schwandner (address as above)
Dr. Johannes Knop (address as above)
Entry in Handelsregister
Register Number: HRB 15481
Register Court: Amtsgericht Regensburg
in accorance with section 27 a of the German VAT act
in accordance with section 55 RStV
Dr. Johannes Knop (address as above)
Accountability for content
The contents of our pages have been created with the utmost care. However, we cannot guarantee the contents' accuracy, completeness or topicality. According to statutory provisions, we are furthermore responsible for our own content on these web pages. In this context, please note that we are accordingly not obliged to monitor merely the transmitted or saved information of third parties, or investigate circumstances pointing to illegal activity. Our obligations to remove or block the use of information under generally applicable laws remain unaffected by this as per §§ 8 to 10 of the Telemedia Act (TMG).
Accountability for links
Responsibility for the content of external links (to web pages of third parties) lies solely with the operators of the linked pages. No violations were evident to us at the time of linking. Should any legal infringement become known to us, we will immediately remove the respective links.
Our web pages and their contents are subject to German copyright law. Unless expressly permitted by law (§ 44a et seq. of the copyright law), every form of utilizing, reproducing or processing works subject to copyright protection on our web pages requires the prior consent of the respective owner of the rights. Unauthorized utilization of copyrighted works is punishable (§ 106 of the copyright law).
This website uses Google Analytics, a web analytics service provided by Google, Inc. (“Google”).
Google Analytics uses “cookies”, which are text files placed on your computer, to help the website analyze how users use the site. The information generated by the cookie about your use of the website (including your IP address) will be transmitted to and stored by Google on servers in the United States. In case of activation of the IP anonymization, Google will truncate/anonymize the last octet of the IP address for Member States of the European Union as well as for other parties to the Agreement on the European Economic Area.
You can refuse the use of Google Analytics by clicking on the following link. An opt-out cookie will be set on the computer, which prevents the future collection of your data when visiting this website: Disable Google Analytics
Further information concerning the terms and conditions of use and data privacy can be found at http://www.google.com/analytics/terms/gb.html or at https://www.google.de/intl/en_uk/policies/. Please note that on this website, Google Analytics code is supplemented by "anonymizeIp" to ensure an anonymized collection of IP addresses (so called IP-masking).
As a contract research organization (CRO), we provide research services to pharmaceutical/biotech companies and academic organizations in form of fee-for-service work.
We are passionate about quality.
We learned biopharmaceutical industry standards from the ground up. A robust set of best practices and skilled staff, paired with lab and tissue culture automation, ensures data quality and reproducibility of results.
We have done it before.
We are seasoned specialists in Lead Discovery across indications, including Oncology, Neuroscience, Inflammation, and Metabolic Disorders. While specializing on predictive, functional assays for challenging targets, e.g. ion channels, transporters, or GPCRs, we are experienced with a wide variety of protein target classes and assay formats.
We value scientific interaction.
Scientific exchange and open communication is key to successful research collaborations. Our small and agile team of subject matter experts is approachable and plays well cross-functionally and internationally.
Integrated, scheduled robotics platform combined with de facto standard reader devices and flexible workstations.
Covers a comprehensive spectrum of functional readouts and scales to various complexity and throughput requirements.
Collection of 120 engineered cell lines covering a broad range of transmembrane targets (GPCRs, Ion Channels, Transporters).
Automated tissue culture facility enabling complex cell maintenance protocols or bulk cell production at constant quality.
75,000 small molecule compound set, optimized for lead-likeness and diversity, free of undesirable chemotypes, verified by LC/UV/MS.
97,000 siRNA sequences targeting the human druggable genome. Different RNA chemistries and intrinsic redundancy to statistically identify false hits.
Anteris medical supports the pharmaceutical, biotech and medical device industries globally by managing the development of combination products, medical devices or in vitro diagnostics. Our broad competencies cover compliance, regulatory affairs combined with innovative, resource-efficient solutions for compliant development and technical documentation as well as marketing and sales expertise.
Metrion Biosciences is an ion channel focused CRO offering integrated drug discovery services, CiPA compliant cardiac safety profiling, phenotypic assays, translational assays and custom screening services on a fee-for-service or collaboration basis. Metrion’s know-how and breadth of services adds value to drug discovery programs by developing and de-risking ion channel modulators as they progress towards nomination for clinical development.
For Dr. Ralf Schwandner, Assay.Works owner and CEO, this year’s ELRIG-Forum in Darmstadt, Germany concluded with a surprise: Our poster on high-throughput screening using a live-cell image-based assay was awarded with the poster prize.
Combining our high-throughput expertise with Metrion's extensive ion channel know-how and electrophysiology based assays, we now can offer a broad spectrum of services to accelerate our client's ion-channel drug discovery programs.
Assay.Works builds on the legacy of the HTS Center of a leading biopharmaceutical company where we provided assay, screening, and quantitative biology services for drug discovery programs across therapeutic areas with high medical need. During our 16-year tenure, we developed and implemented more than 250 screens spanning all major drug target classes, and generated over 100,000,000 data sets.
Founder and CEO
Biologist and seasoned Lead Discovery specialist with 18 years of experience in the biopharmaceutical industry. Prior to founding Assay.Works, he served as head of Amgen‘s HTS center of excellence at Regensburg, Germany (Amgen Research GmbH).
Founder and COO
Biochemist with 16 years of industry experience in Lead Discovery. Most recently, he was head of Research Operations at Amgen Research GmbH, where he managed Sample Management, cell-based Lead Profiling, Cell Production, Informatics, and EH&S.